Information Provided By: 
Fly News Breaks for June 11, 2019
TXMD
Jun 11, 2019 | 06:47 EDT
JPMorgan analyst Chris Schott lowered his price target for TherapeuticsMD to $6 from $8 while keeping an Overweight rating on the shares. The analyst reduced his estimates after the company's 2019 guidance coming in below his expectations, reflecting "more challenging" gross-to-net dynamics for Imvexxy as well as a softer outlook for its vitamin business. However, Schott continues to see Imvexxy, Bijuva and Annovera as well positioned in their respective markets, which he believes should support "very strong uptake" over the next several years.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
